Not that I'm aware.
... unless the media is also very late to the party:
INO Corona
INO Motley Fool
Quote
"The bad news is that Inovio has never actually developed a commercial-stage vaccine. Despite being in business for 40 years, the company is only now on the cusp of generating late-stage data for one of its DNA-based therapies. Specifically, Inovio is slated to roll out top-line data for VGX-3100 as a treatment for cervical dysplasia in the fourth-quarter of 2020.
Another worrying sign is that this isn't the first time Inovio's stock has skyrocketed in response to an infectious disease threat. In 2016, for instance, the biotech's shares took flight after it announced plans to tackle the Zika virus. Per the company's latest clinical update in early 2020, however, its Zika virus product candidate hasn't even made it past a phase 1 trial yet. So investors should probably take this hype over a COVID-19 virus vaccine with a huge grain of salt.
Time to buy?
If your sole purpose is to own a company likely to benefit from the COVID-19 threat, Inovio probably isn't your best bet. The company has never brought a product to market in four decades, much to the detriment of long-suffering shareholders. Since going public, in fact, Inovio's stock has produced a negative return on capital of 92.7%. Perhaps this story will change for the better with a positive late-stage readout for VGX-3100 later this year. But until then, investors should probably curb their enthusiasm. "